{
    "nctId": "NCT01910298",
    "briefTitle": "Efficacy Study of Single Stage Breast Reconstruction in Female Participants With Mastectomy",
    "officialTitle": "A Prospective, Multicenter, Controlled Study of Implant-based Breast Reconstruction, Measuring the Safety, Efficacy and Outcomes, of Immediate Single Stage Breast Reconstruction With Strattice\u2122 Reconstructive Tissue Matrix Versus Immediate Two Stage Breast Reconstruction Without Strattice\u2122 TM (ESSBR-Efficacy of Single Stage Breast Reconstruction)",
    "overallStatus": "TERMINATED",
    "conditions": "Mastectomy and Breast Reconstruction",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 131,
    "primaryOutcomeMeasure": "Mean Number of Planned and Unplanned Post-mastectomy Surgical Interventions Per Participant on the Reconstructed Breast, Within 12 Months of the Initial Study Surgery (ISS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female 18 years or older\n* A candidate for both arms of the study involving immediate breast reconstruction post-skin sparing mastectomy (unilateral or bilateral) DTI with the use of Strattice\u2122 Reconstructive Tissue Matrix (TM), 2 stage with use of Tissue Expander through exchange to Implant without support of a mesh or autologous tissue)\n* An American Society of Anesthesiologists (ASA) Physical Status Classification of 1 or 2\n* Estimated life expectancy \\> 3 years\n* Able and willing to return for all scheduled and required study visits\n* Able to provide written informed consent for study participation\n\nExclusion Criteria:\n\n* Clinically significant systemic disease, as determined by the Investigator, which could affect study participation or study results\n* Received neo-adjuvant, inductive chemo-therapy (except Herceptin, or other targeted therapy) within 4 weeks prior to mastectomy\n* Previous radiation therapy to either breast at any time\n* Predicted permanent implant size that is greater than or equal to 500 grams (gms), per Investigator assessment\n* Body mass index (BMI) \\<17 or \\> 30\n* Co-morbid factors which predispose to postoperative infection, e.g. diabetes, collagen vascular disease, chronic steroid (except inhalers)/immunosuppressant use, immune deficiency, or co-existent infection\n* Pregnant or lactating\n* 3rd degree ptosis\n* Prior breast surgery including breast reduction, augmentation, mastopexy, quadrectomy, and partial mastectomy with reduction of the skin envelope\n* Prior use of a device (mesh or matrix) in the Breast\n* Concomitant unrelated condition of breast/chest wall/skin that, as determined by the investigator, could adversely affect the surgical outcome (e.g. significant chest wall abnormalities including pectus excavatum or pectus carinatum)\n* Planned autologous tissue flap in addition to prosthetic implant\n* Use of permanent expander implants such as Becker expanders or the Natrelle\u2122 Permanent expander 150\n* Current alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or drug abuse or addiction\n* Currently enrolled or plans to enroll in another clinical trial unless it is: a registry, a retrospective study, a neo-adjuvant chemotherapy trial (as long as the chemotherapy regimen has been stopped 4 weeks prior to mastectomy), or a hormone/anti-hormonal therapy trial\n* Any of the conditions identified within the labelled contraindications, i.e. sensitivity to porcine derived products or polysorbate 20.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}